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ABSTRACT
Standard treatment regimens consisting of surgery, radiation and chemotherapy have proven
ineffective for the treatment of high-grade gliomas such as glioblastoma multiforme (GBM). An
effective cure requires elimination of nests of tumor cells that have migrated from the resection
margin and infiltrated normal brain. A number of localized therapies, including light-based
approaches such as photodynamic therapy (PDT) and photochemical internalization (PCI) are
currently under investigation for the management of GBM patients.
Several studies have demonstrated a high degree of synergy between PDT and bleomycin, via the
PCI mechanism, in a variety of in vitro and in vivo models, including glioma cell lines. The purpose
of this study was to examine the efficacy of combined treatments consisting of PDT and the
chemotherapeutic agent, 5-fluorouracil (5-FU) in a 3-dimensional spheroid model consisting of
F98 rat glioma cells. Spheroids were incubated with a photosensitizer (aluminum phthalocyanine
disulfonate; AlPcS2a) and irradiated with 670 nm laser light. Three different wash protocols (0, 4
and 24 h) were employed to determine whether any observed interactions between PDT and 5-FU
could be attributed to the PCI mechanism, or were simply due to different cytotoxic pathways of
the two treatment modalities.
Although the combined PDT + 5-FU treatments resulted in greater suppression of spheroid growth
compared to either treatment alone, no statistically significant differences in growth effects were
observed between 0 and 4 h wash protocols suggesting that the combined treatment effects were
due to different mechanisms of cytotoxicity, rather than a PCI effect.
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INTRODUCTION
1.1 Glioblastoma Multiforme
High-grade brain tumors such as glioblastoma multiforme (GBM) originate from glial cells located
in the central nervous system (CNS). CNS tumors are relatively rare accounting for only about 2%
of all cancer deaths (Chandana et al. 2008). GBM is the most common type of glioma accounting
for approximately 50% of all gliomas and 15.6% of all primary brain tumors (Table 1). Due to
their aggressive and infiltrative nature, GBMs are one of the most deadly types of cancer with one
and five-year survival rates of 35% and 4.7%, respectively (Table 2). A variety of GBM subgroups
exist but the most aggressive is also the most commonly seen in humans (Holland 2000). Due to
the poor prognosis and limited efficacy of current treatments, significant efforts have been devoted
to develop alternative treatments including the use of hybrid viruses, gene therapy and a wide
variety of immunotherapeutic approaches (Holland 2000). GBMs pose significant therapeutic
challenges due to a number of factors including their heterogeneity (multiforme) and invasive
behavior. The tumors consist of both rapidly propagating cells as well as regions of necrosis.
Numerous genetic alterations are associated with GBM including mutations in the epidermal
growth factor receptor (EGFR) and phosphatase and tensin homolog (PTEN) (Alifieris and
Trafalis 2015). The collective effect of these mutations is to disrupt the cell cycle resulting in
uncontrollable cell division.
The primary treatment for GBM is surgical resection with the aim of removing as much of the
tumor as possible. Unfortunately, due to the infiltration of glioma cells into normal brain, surgery
is not sufficient to eradicate the disease. A complicating factor for achieving complete resection is
the inability to visualize infiltrating glioma cells with current imaging modalities such as magnetic
resonance imaging. Secondary treatments involving radiation and chemotherapy are typically used
in an attempt to eradicate infiltrating glioma cells however, as evidenced from high recurrence
1

rates, these treatments are ineffective thus providing the rationale for alternative localized
treatment approaches, including light-based techniques such as photochemical internalization
(PCI) aimed at eliminating infiltrating cells in normal brain.

Histology
N
Tumors of Neuroepithelial Tissue
Pilocytic astrocytoma
Diffuse astrocytoma
Anaplastic astrocytoma
Glioblastoma
Oligodendroglioma
Ependymal tumors
Glioma malignant, NOS
Neuronal and mixed neuronal-glial
tumors
Embryonal tumors
Tumors of Cranial and Spinal Nerves
Nerve sheath tumors
Tumors of Meninges
Meningioma
Lymphomas and Hemopoietic
Neoplasms
Lymphoma
Germ Cell Tumors and Cysts
Tumors of Sellar Region
Tumors of the pituitary
Unclassified Tumors
Hemangioma
Neoplasm, unspecified
TOTAL‡

101,825
4,741
8,535
5,621
50,872
4,020
6,304
6,765

Total
% of All Median
Tumors
Age
31.2
56
1.5
13
2.6
47
1.7
54
15.6
64
1.2
43
1.9
44
2.1
38

Rate
6.60
0.33
0.56
0.37
3.19
0.27
0.42
0.46

4,036

1.2

27

0.27

3,790
26,564
26,548
121,110
116,986

1.2
8.1
8.1
37.1
35.8

9
55
55
65
65

0.26
1.69
1.69
7.71
7.44

7,122

2.2

65

0.46

6,919
1,464
50,709
47,958
17,917
3,934
13,895
326,711

2.1
0.4
15.5
14.7
5.5
1.2
4.3
100

65
17
50
51
64
49
70
59

0.44
0.10
3.32
3.13
1.16
0.26
0.90
21.03

Table 1 Incidence rates of CNS tumors. Rates are per 100,000 and are age-adjusted to the 2000 U.S. standard population (Ostrom
et al. 2013).
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Histology

N

1-Yr

5-Yr

%

%

Pilocytic astrocytoma

3,301

97.9

94.4

Diffuse astrocytoma

5,902

71.3

47.3

Anaplastic astrocytoma

3,472

60.1

26.5

Glioblastoma

28,212

35.0

4.7

Oligodendroglioma

3,226

93.8

79.1

Anaplastic oligodendroglioma

1,257

80.6

50.7

Ependymal tumors

2,517

93.9

83.4

Oligoastrocytic tumors

1,820

87.2

61.0

Glioma malignant, NOS

4,014

61.1

43.4

469

90.2

74.5

2,666

81.5

61.3

1,573

88.2

71.1

Primative neuroectodermal tumor

651

76.4

49.5

Atypical teratoid/rhabdoid tumor

181

48.1

28.0

Other embryonal histologies

261

76.3

54.2

Meningioma

1,099

82.6

64.7

Lymphoma

4,500

47.6

29.1

66,830

56.9

33.8

Neuronal and mixed neuronal-glial tumors
Embryonal tumors
Medulloblastoma

Total: All Brain and Other Nervous System

Table 2 One- and five-year relative survival rates for selected malignant brain and central nervous system tumors by histology
(Ostrom et al. 2013).

1.2 Photodynamic Therapy
PDT is the use of light and a photosensitizer to cause cell damage (Figure 1). Following
photosensitizer administration, light of a particular wavelength matching an absorption resonance
of the photosensitizer, is used to excite the molecule. The excited photosensitizer interacts with
ground state molecular oxygen resulting in the generation of singlet molecular oxygen, a potent
reactive oxygen species, resulting in cell death (Figure 2) (Robertson, Evans, and Abrahamse
2009). Like radiation therapy, PDT is an oxygen-mediated treatment and, as such, efficacy is
sensitively dependent on the presence of oxygen during treatment.

3

Figure 1 Overview of PDT (Godfrey 2018)

PDT is somewhat limited by the poor penetration depth of light in biological tissues (typically a
few mm) and therefore light must be delivered in close proximity to the tumor. This is typically
accomplished using laser light coupled into optical fibers in contact with or embedded into the
tumor and, as such, this approach provides a high degree of tumor selectivity which is important
since most photosensitizers have rather poor specificity (Robertson, Evans, and Abrahamse 2009).
PDT efficacy depends on a number of factors including photosensitizer type, light dose and dose
rate, and tissue oxygenation status.

Figure 2 PDT toxicity via generation of oxygen radicals (Joy et al. 2014) .

Photosensitizers with strong absorption in the red to near-infrared are desirable since light has
optimum penetration in biological tissues in this wavelength range. This optical window is due to
the limited absorption of tissue chromophores in the red to near-infrared region of the
4

electromagnetic spectrum (Chester, Martellucci, and Scheggi 1991). Light delivered at low dose
rates has been found to be more effective compared to high dose rate PDT in a number of in vitro
and in vivo models and hence, provides the rationale for the low dose rate used in this work
(Madsen et al. 2006). High dose rates have been shown to result in photobleaching of the sensitizer
thus rendering it incapable of producing singlet oxygen – the primary cytotoxic species in PDT.
From a mechanistic standpoint, PDT has been shown to affect various levels of cell signaling, e.g.
it can increase the levels of intracellular calcium in cancer cells as well as the level of ceramide, a
potent inducer of apoptotic cell death. PDT has also been shown to disrupt the epidermal growth
factor receptor (EGFR) which is known to help tumors proliferate. Transcription factors are also
affected as well as cytokines, which are proteins that control immune responses and other related
functions (Robertson, Evans, and Abrahamse 2009).

Figure 3 PDT-induced types of cell death (Abrahamse and Hamblin 2016).

PDT can induce either apoptosis, autophagy or necrosis depending on a number of factors
including type of photosensitizer, light dose and dose rate (Figure 3). Unlike ionizing radiation
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and many chemotherapeutic agents, PDT does not exert its effects via DNA damage (Robertson,
Evans, and Abrahamse 2009).
1.3 The use of PDT for the treatment of brain tumors
PDT has been investigated as an adjuvant for the treatment of malignant gliomas for approximately
35 years (Quirk et al. 2015). Although numerous clinical trials have been initiated, the vast
majority have consisted of uncontrolled phase I/II studies. Due to differences in methodology and
types of malignant brain tumors treated, it has been very difficult to evaluate PDT efficacy from
these limited trials. In order for PDT to gain widespread clinical acceptance, it must demonstrate
outcomes similar to, and hopefully better, than those achievable with the current standard of care
consisting of surgical resection + radiation + temozolomide which results in a median overall
survival of 14.6 months and median progression free survival of 6.9 months for newly diagnosed
GBM (Stupp et al. 2005).
In a large phase I/II clinical trial conducted in Melbourne, newly diagnosed GBM patients were
treated with high light dose PDT (240 J cm-2) using a first generation photosensitizer (Stylli et al.
2005). Mean overall survival (14.3 months) compared favorably with the current standard of care.
The results of a clinical trial involving 112 patients with newly diagnosed GBM in Toronto were
rather disappointing (mean overall survival of 7.6 months)(Muller and Wilson 2006). The modest
results were likely due to the low light dose used (58 J cm-2). Additional trials involving both
newly diagnosed and recurrent GBM patients in Munich (Beck et al. 2007), Innsbruck (Beck et al.
2007) and Dundee (Eljamel, Goodman, and Moseley 2008) have failed to show substantial
improvements in both overall survival and progression free survival compared to the standard of
care. Results of two recent small scale PDT trials in Japan were rather encouraging (Akimoto,
Haraoka, and Aizawa 2012; Muragaki et al. 2013) as they demonstrated significant improvement
6

in both overall survival and progression free survival in newly diagnosed and recurrent GBMs.
The same approach, consisting of a new generation photosensitizer (talaporfin sodium) in
combination with spot irradiation of the resection margins, was used in both trials.
Overall, the results of PDT trials for malignant gliomas have been relatively modest thus
providing the rationale for alternative treatment approaches such as PCI.
1.4 Photochemical Internalization
Photochemical Internalization (PCI) is a modified form of PDT which has been used to enhance
the uptake of a wide variety of macromolecules including proteins, genes, oligonucleotides and
chemotherapeutic agents such as bleomycin (Table 3). The PCI process is illustrated in Figure 4.
As shown in panel A, many macromolecules enter cells via endocytosis, which results in their
encapsulation in endosomes.

Figure 4 The PCI process (Moses and You 2013).

In order to exert their therapeutic effect, macromolecules must be released from the endosomes
into the cytosol where they can diffuse to the target (typically the DNA). Unfortunately, only a
small fraction of macromolecules escape the endosomes prior to endosome-lysosome fusion which
results in the degradation of the macromolecule thus rendering them ineffective. In PCI (panel B),
7

a membrane localizing photosensitizer is administered prior to administration of the therapeutic
macromolecule. Following endocytosis, the photosensitizer laden endosome walls are exposed to
light and the resultant PDT effect ruptures the membranes thus releasing the macromolecules into
the cytosol prior to endosome-lysosome fusion, this process is known as the “light after” approach
(Weyergang et al. 2011).

Cancer type

In vivo/In vitro

Uterus cancer

In vitro

Head and Neck
cancer

In vitro

Breast cancer

In vitro

Photosensitizer

Cytotoxic agents

TPPS4 ,TPPS2a
tetraphenyl porphine
AlPcS2a
TPPS2a
TPPS2a,TPCS2a
AlPcS2a
DPc,TPCS2a

In vitro

AlPcS2a

TPPS2a
Colon cancer

MOC31‐gelonin,
Trastuzumab–saporin
Cetuximab−saporin

TPCS2a
In vivo

AlPcS2a

Ovarian cancer

In vitro

TPPS2a

Sarcoma

In vitro
In vivo

Bladder cancer

Glioma

Skin cancer

In vitro

Bleomycin
Gelonin
EGF–saporin
(liposomally encapsulated
saporin)

TPCS2a,AlPcS2a

IM7-saporin
Gelonin

TPPS2a

Bleomycin
Gelonin

AlPcS2a
TPCS2a

Bleomycin
scFvMEL/rGel

TPPS2a,AlPcS2a

In vivo

TPCS2a

In vitro

AlPcS2a

In vivo

AlPcS2a

In vitro

(Pål Kristian Selbo, Sandvig, et al. 2000)
(Olsen et al. 2013)
(Wai et al. 2007)
Ranpirnase
(Liebers et al. 2017)
Saporin
(Lai et al. 2008)
PAMAM‐saporin
(Wang et al. 2012)
(Pål Kristian Selbo et al. 2012)
EGF-saporin, Doxorubicin
(Olsen et al. 2013)
Gelonin, IM7-saporin
(Bostad et al. 2014)
(DPc/m) Doxorubicin
(Lu et al. 2011)
scFvMEL-rGel
(Eng et al. 2018)
Doxorubicin,Gelonin
Cetuximab-Saporin

AlPcS2a,TPCS2a

In vivo

References

Bleomycin
Doxorubicin
Bleomycin
Bleomycin,ETXp

TPPS2a
AlPcS2a

In vivo

AlPcS2a, TPPS2a

Prostate cancer

In vitro

TPPS2a

Pancreatic cancer

In vitro

TPCS2a

Lung cancer

In vitro

AlPcS2a, 3‐THPP

2

(Pål Kristian Selbo, Sivam, et al. 2000)
(Berstad, Weyergang, and Berg 2012)
(Wai et al. 2007)
(Pl Kristian Selbo et al. 2001)
(Pl Kristian Selbo et al. 2001)
(Weyergang, Selbo, and Berg 2006)
(Fretz et al. 2007)
(Bostad et al. 2014)
(Dietze et al. 2003)
(O.-J. Norum, Giercksky, and Berg 2009)
(Berg et al. 2005)
(Arentsen et al. 2014)
(Pål K. Selbo et al. 2009)
(Gederaas et al. 2017)
(Shin et al. 2018)
(Mathews et al. 2012)
(Hirschberg et al. 2009)

Cetuximab−saporin
Gelonin

(Wai et al. 2007)
(Prasmickaite et al. 2002)

scFvMEL/rGel
cetuximab−saporin
IM7-saporin
IM7-saporin
anti-CD133
MOC31‐gelonin

(Pål K. Selbo et al. 2009)
(Wai et al. 2007)
(Bostad et al. 2014)
(Bostad et al. 2014)
(Bostad et al. 2013)
(Pål Kristian Selbo, Sivam, et al. 2000)

Table 3 Summary of macromolecules used in PCI.
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1.5 Cell line
F98 rat glioma cells were used in this study (Figure 5). The cells were originally derived from
transformed fetal Fischer rat brain cells following exposure to a known carcinogen (ethylnitrosourea) (Ko, Koestner, and Wechsler 1980). The F98 cell line has been used in a number of
in vitro and in vivo studies evaluating the effects of a variety of therapeutic modalities including
PDT (Madsen, Kharkhuu, and Hirschberg 2007). The cell line shares many characteristics with
human GBM including infiltrative behavior and rapid proliferation. Furthermore, when F98 cells
are implanted into brains of Fischer rats, tumors develop rapidly and are highly reproducible from
animal to animal. The weak immunogenicity of F98 tumors is a substantial advantage over other
rat glioma cell lines which have been shown to evoke strong immune responses (Barth and Kaur
2009).

Figure 5 F98 rat glioma cells (ATCC 2016).

1.6 Spheroids
The majority of in vitro therapeutic studies have been conducted on cells arranged in monolayers
since this is an easy model to maintain. In this configuration, all cells have adequate access to
nutrients and oxygen in the cell medium. Unfortunately, monolayers do not mimic the threedimensional nature of solid tumors and the resultant nutrient and oxygen gradients affect
therapeutic response, especially for oxygen-mediated therapies such as ionizing radiation and
9

PDT. Spheroids are three-dimensional cell clusters that closely resemble the tumor environment
(Santini, Rainaldi, and Indovina 2000). Of particular relevance to this work is the ability of
multicellular spheroids to mimic the oxygen gradients found in tumors. As shown in Figure 6, as
spheroids grow beyond a diameter of 250 - 300 µm diameter, a central core of necrosis develops
due to the limited diffusion of oxygen from its source (Dubessy et al. 2000).

Figure 6 Three-dimensional spheroid consisting of F98 cells illustrating the characteristic cell viability zones, modified from
(LaBonia et al. 2016)

Although cells in the necrotic core are dead and therefore not of relevance in therapeutic studies,
cells adjacent to the necrotic core are hypoxic and therefore resistant to PDT. Due to the lack of
oxygen, these cells are not proliferating and are therefore found in the quiescent (G 0) stage of the
cell cycle. As in solid tumors, these resistant cells are treatment limiting. The outermost layer of
cells in the spheroid are in a relatively oxygen rich environment as they are closest to the source
of oxygen, i.e., the medium and therefore they proliferate rapidly. In addition to the oxygen
gradients, spheroids are also capable of mimicking photosensitizer gradients found in tumors
including the effects of the extracellular matrix which may impede diffusion of the sensitizer. Since
spheroid diameters were approximately 250 – 300 µm at the time of laser irradiation, light
distributions were relatively uniform throughout the spheroid.
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Although the lack of a vasculature is a drawback of the spheroid model it may be possible to
address this limitation by placing spheroids on the surface of the developing chick embryo. For
example, De Magalhães et al. 2010 found significant vascularization of human glioma spheroids
7 days following implantation on the chick chorioallantoic membrane.
1.7 5-Fluorouracil
A number of chemotherapeutic agents have been used in the treatment of GBM. Ideally these drugs
should have the ability to cross the blood-brain barrier followed by entry into cells through the
plasma membrane. This typically occurs only for low molecular weight and/or lipophilic drugs via
passive diffusion across the cell membrane (Mathews et al. 2012). Unfortunately, many
chemotherapeutic drugs are large and hydrophilic thus requiring active transport into cells via
endocytosis (Zaniboni, Prabhu, and Audisio 2005). As discussed previously, PCI may be used to
enhance the efficacy of these macromolecules. In the majority of studies reported to date, PCI has
been used to enhance the efficacy of bleomycin – a 1.5 kDa glycopeptide antibiotic that causes
single and double strand DNA breaks similar to the damage caused by ionizing radiation. PCI has
been shown to enhance the efficacy of bleomycin in a number of different cell lines including
gliomas (Madsen et al. 2009). 5-Flurouracil (5-FU) is an antimetabolite (Figure 7) that has received
FDA approval for the treatment of a wide variety of cancers including colon, rectal, breast, head
and neck, cervical and a number of gastrointestinal tumors.(Longley, Harkin, and Johnston 2003).
5-FU acts primarily as a thymidylate inhibitor. Inhibition of this enzyme blocks synthesis of
pyrimidine thymidine which is required for DNA replication. Ultimately, administration of 5-FU
results in preferential death of rapidly dividing cancer cells. Other mechanisms of action include
the downregulation of various RNA processes and activation of the tumor suppressor gene, p53
resulting in apoptotic cell death.(Longley, Harkin, and Johnston 2003). 5-FU is a small molecule
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(130 Da) that enters the cytoplasm via passive diffusion. Nevertheless, a recent study has shown
that PDT and 5-FU interact in a synergistic manner akin to that observed with PCI (Christie et al.
2017).

Figure 7 Molecular structure of 5-FU (He et al. 2015).

1.8 Photosensitizer
The photosensitizer used in this work, AlPcS2a, is a phthalocyanine derivative containing two
charged sulfonate groups linked to phthalic subunits in adjacent positions and an aluminum metal
ion incorporated at its center (Figure 8). Of particular relevance to PCI is that AlPcS2a is an
amphiphilic molecule, i.e., it has both hydrophilic and lipophilic properties and therefore it
localizes in cellular membranes following systemic administration (Hirschberg and Madsen 2017).
The lipophilic phthalocyanine skeleton of AlPcS2a localizes in the lipophilic interior of the cellular
membrane while the sulfonate groups dissolve in the hydrophilic outer layer of the membrane.

Figure 8 Molecular structure of AlPcS2a (Pål Kristian Selbo et al. 2002).
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1.9 Scope of Work
The purpose of this work was to determine the efficacy of combined 5-FU and AlPcS2a-PDT in an
in vitro model consisting of three-dimensional multicell F98 glioma spheroids. Specifically,
different wash protocols were investigated to determine whether any observed interaction between
the two treatments could be attributed to the PCI mechanism, or was simply due to different
cytotoxic pathways of the two modalities.

13

MATERIALS AND METHODS
2.1 Maintenance of Cell Line
All experiments were done at the University of Nevada, Las Vegas. The F98 rat glioma cell line
used in this experiment was propagated in T-25 BD Falcon flasks with a vented cap and the media
used was Dulbecco’s Modified Eagle Medium (DMEM, Thermo Fisher Corp., Carlsbad CA)
modified with 15 ml of HEPES, 5 ml of Pen-Strep (10,000 units/ml Penicillin, 10,000 µg/ml
Streptomycin, Thermo Fisher Corp., Carlsbad CA) and 50 ml of fetal bovine serum (FBS; Thermo
Fisher Corp., Carlsbad CA). Cells were kept in an incubator at the following settings: 37°C, 5%
CO2, 80% humidity. The protocol to culture the cells was as follows: at cell confluence, the
medium was removed and the adherent F98 monolayer was washed using 5-7 ml of phosphate
buffer solution (PBS; Thermo Fisher Corp, Carlsbad CA). Following PBS removal, the monolayer
was treated with 5 ml of Gibco Trypsin-EDTA for five minutes. The detached cells were then used
to make spheroids.
2.2 Creation of Spheroids
Following cell detachment, PBS (7-10 ml) was added to the cells and the resultant solution was
transferred to a 15 ml centrifuge tube which was placed into a centrifuge and spun at a setting of
400 g for 4 minutes. Following centrifugation, the cells formed a pellet at the bottom of the tube.
The excess PBS was removed, replaced with fresh PBS and vortexed. This process was then
repeated. Media was then added instead of PBS followed by vortexing to disperse the pellet. Cells
were counted using a C-Chip (SKC Inc., Covington CA). The spheroids were generated using a
total of 12000 cells per ml. The cells in 100 µl of medium were alloquated into individual wells of
a Costar 96 well round bottom ultra-low attachment plate (Fisher Scientific, Inc., Pittsburgh PA),
centrifuged at 400 g for 4 min. and placed in an incubator for 45-60 min. Following incubation,
the plate was then centrifuged a second time at 800 g for 8 min. Cells in each well were visually
14

inspected using a microscope to confirm a disc shaped appearance. The plate was placed in the
incubator (37°C, 5% CO2, 80% humidity) for 48 h to allow the spheroids to assume their
characteristic 3-D shape. In the case of the PCI experiments, five plates were centrifuged: dark
controls, PDT controls, and 3 PCI experimental plates. In all cases, the mean spheroid diameter
prior to the initiation of treatment was 250 – 300 µm.
2.3 5-FU Procedure
Five mg/ml of 5-FU in DMSO was diluted to a 1 mg/ml stock solution with PBS. The stock
solution was then diluted with DMEM to the following concentrations: 0.25, 0.5 and 1 µg/ml.
Controls (0 µg/ml) consisted of spheroids in DMEM only. Two days following creation, spheroids
were incubated in various 5-FU concentrations. Each well consisted of 200 µl 5-FU-DMEM
solution (or DMEM in the case of controls) which was replaced with new medium 5 days following
incubation and, as such, spheroids were incubated with various concentrations of 5-FU for 5 days.
2.4 Laser Setup
The setup for laser irradiation is shown in Figure 9. Spheroids were irradiated with a 670 nm diode
laser (Intense, North Brunswick NJ) coupled to a 200 µm dia. optical fiber (Medlight SA,
Ecublens, Switzerland). A ring stand was used in combination with a cardboard cutout which
allowed the plates to be elevated above the laser thus facilitating spheroid irradiation from the
bottom of the plate. The cardboard cutout ensured irradiation of only three columns at a time. In
all cases, spheroids were irradiated with a 9 cm dia. beam at an irradiance of 5 mW/cm2 for 60,
120, or 200 s corresponding to radiant exposures of 0.3, 0.6, or 1.0 J cm-2, respectively. On a given
plate, each irradiated group was separated by two empty columns in order to minimize the effects
of light scattering and its contribution to light dose to spheroids in the other radiant exposure
groups.
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Figure 9 Experimental setup showing laser irradiation of 96-well plate.

2.5 Photodynamic Therapy Procedure
Forty-eight hours following centrifugation, spheroids were examined with a light microscope to
ensure their characteristic 3D shape prior to PDT treatments. The photosensitizer AlPcS2a (Frontier
Scientific, Inc., Logan UT) was diluted to a concentration of 2 µg/ml with DMEM and 100 µL of
this solution was added to each spheroid in the 96 well plate (one spheroid per well). The plate
was covered with aluminum foil to minimize background light exposure and placed in an incubator
for 18 h. Following incubation, the photosensitizer was removed from each well using a wash
protocol consisting of replacing the photosensitizer solution with 100 µl PBS. A total of four
washes were performed to ensure complete removal of the sensitizer. The spheroids were then
irradiated either immediately following the wash cycle (0 h protocol), 4 h later (4 h protocol), or
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24 h later (24 h protocol) according to the light protocols described in section 2.4. Following PDT
treatments, the plates were placed in an incubator for 48 h after which the first spheroid volumes
were recorded. All procedures described in this section were performed under subdued light
conditions in order to minimize the possibility of ambient light-induced PDT toxicity.
2.6 Combined PDT + 5-FU Procedure
Except for the addition of 5-FU, the combined treatment protocol was identical to the PDT
procedure described in Section 2.5. 5-FU was diluted with DMEM to a concentration of 0.25 µg/ml
and 100 ul of this solution was added to each well containing a PDT + 5-FU-designated spheroid.
In the case of the 0 h protocol, spheroids were irradiated immediately following the addition of 5FU. For the four hour protocol, spheroids were irradiated 4 h after 5-FU incubation. This is the
standard PCI protocol employing bleomycin. In the case of the 24 h protocol, 5-FU was added 24
h after the last wash followed immediately by light irradiation. The three protocols are summarized
below.
0 h Protocol
18 h AlPcS2a incubation → wash → wash → wash → wash --- 5-FU → light
4 h Protocol
18 h AlPcS2a incubation → wash → wash → wash → wash → 5-FU -- 4 h → light
24 h Protocol
18 h AlPcS2a incubation → wash → wash → wash → wash → 24 h → 5-FU ---light

Following light exposure, the plates were placed in an incubator for 48 h after which the first
spheroid volume measurements were made.
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2.7 Measurements and Analysis
In all cases, treatment efficacy was determined from spheroid growth kinetics. A light microscope
with a calibrated eyepiece was used to measure spheroid diameters. For each spheroid, the mean
of two diameter measurements (vertical and horizontal) were recorded and the volume calculated
assuming a perfect sphere. Spheroids (12 per experimental group) were followed for
approximately two weeks. Spheroids were measured 5, 8, 10 and 13 days following treatment and
normalized spheroid volume was plotted to determine treatment efficacy. Normalized volume was
determined by calculating the ratio of volumes of treated to untreated controls on the last
measurement day. In order to determine the degree of interaction between PDT and 5-FU, the
following equation was used (Drewinko et al. 1976):

𝛼=

𝑉 𝑃𝐷𝑇 ∗ 𝑉 5−𝐹𝑈
𝑉𝑃𝐷𝑇+5−𝐹𝑈

where VPDT, V5-FU and VPDT+5-FU represent normalized volumes of spheroids subjected to PDT, 5FU and PDT + 5-FU. In this scheme, an alpha value of one represents an additive effect while
alpha values less than or greater than one represent antagonistic or synergistic effects respectively.
Student t-tests were performed to determine whether the results of the different wash protocols
were statistically significant (www.graphpad.com).
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RESULTS
3.1 5-FU dose dependence
The effects of 5-FU on F98 spheroids are shown in Figure 10. Normalized spheroid volumes
ranged from 0.72 at the lowest 5-FU concentration investigated (0.12 µg/ml), to 0.17 at the highest
concentration (0.5 µg/ml). Based on these results, a concentration of 0.12 µg/ml 5-FU was used
for all subsequent PCI studies. The rationale for this choice is based on the objective of PCI which
is to enhance the effects of therapeutic drugs at relatively low concentrations.

5-FU Titration

Spheroid Volume (% of Control)

1

0.8

0.6

Control
0.12 µg/ml

1
0.4

0.25 µg/ml
0.719

0.50 µg/ml

0.2

0.402
0.166

0
Treatment
Figure 10 Effects of 5-FU on F98 spheroid growth. Spheroids were incubated in varying concentrations of 5-FU for 5 days.
Normalized spheroid volumes were recorded 13 days following the start of incubation. Each data point represents the mean of 6
trials (12 spheroids per trial) and error bars represent standard deviations

3.2 PDT results
The effects of PDT on spheroid growth are illustrated in Figure 11 for three different wash
protocols. The purpose of the wash was to remove excess photosensitizer from the wells prior to
light irradiation. In standard PDT protocols, spheroids are irradiated immediately following the
wash cycle, i.e., the 0 h protocol (Figure 11a). The data in Figure 11a show a moderate PDT dose
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response ranging from 0.86 ± 0.06 at a radiant exposure of 0.3 J cm-2 to 0.69 ± 0.07 at 1.0 J cm-2.
A similar dose response was observed for spheroids subjected to PDT after a 4h wash protocol
(Fig. 11b) where normalized volumes ranged from 0.97 ± 0.08 for spheroids exposed to 0.3 J cm2

, to 0.73 ± 0.09 following exposures to 1.0 J cm-2. PDT-treated spheroids subjected to the 24 h

wash protocol demonstrated only a marginal response ranging from 1.03±0.04 for 0.3 J cm -2 to
0.89 ± 0.04 for a radiant exposure of 1.0 J cm-2 (Figure 11c). As evidenced from the student t-tests
summarized in Table 4, statistical significance was demonstrated in most cases. Overall, the data
suggest that the 0 h wash protocol was the most effective for inhibiting spheroid growth while the
24 h protocol was the least effective.
0 h vs. 4 h
Radiant Exposure
p-value
-2
(J cm )
0.3
0.024
0.6
0.040
1.0
0.317
p < 0.05 is considered statistically significant

4 h vs. 24 h
Radiant Exposure
(J cm-2)
0.3
0.6
1.0

Table 4 Evaluation of statistical significance for different wash protocols
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p-value
0.139
0.004
0.001

Spheroid Volume (% of Control)

A

PDT - 0 h Protocol
1
0.8
DC
0.6
0.96
0.4

0.3 J
0.86

0.77

0.69

0.6 J
1.0 J

0.2
0
Treatment

B

PDT - 4 h Protocol

Spheroid Volume (% of Control)

1.2
1
0.8

DC
0.3 J

0.6
1.02
0.4

0.97

0.84

0.6 J
0.73

1.0 J

0.2
0
Treatment

C

PDT - 24 h Protocol

Spheroid Volume (% of Control)

1.2
1
0.8
0.6

DC
0.3 J
1.05

1.03

0.94

0.4

0.89

0.6 J
1.0 J

0.2
0
Treatment

Figure 11 PDT effects on F98 glioma spheroids subjected to three different wash protocols. Normalized spheroid volumes were
recorded 13 days following light exposure. Each data point represents the mean of 6 trials (12 spheroids per trial) and error bars
represent standard deviations.
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3.3 PDT + 5-FU results
Results of the combined experiments are summarized in Figure 12. Significant treatment effects
were observed for spheroids subjected to the 0 and 4 h wash protocols. For example, normalized
volumes for 0 h spheroids ranged from 0.60±0.04 (0.3 J cm-2) to 0.35±0.04 (1.0 J cm-2) while
normalized volumes for the 4 h spheroids ranged from 0.65±0.04 (0.3 J cm-2) to 0.40±0.03 (1.0 J
cm-2). In both cases, the greatest effect was observed at the highest radiant exposure. In contrast,
treatment efficacy was observed to be lower for 24 h spheroids (Figure 12c) which showed no
dependence on radiant exposure (0.68±0.04 for 0.3 J cm-2 and 0.64±0.02 for 1.0 J cm-2). In order
to obtain a quantitative measure of the degree of interaction between the two treatment modalities,
alpha values were calculated from equation (1) and summarized in Table 5. The data show a
marginal synergistic effect at the highest radiant exposure for both 0 and 4 h spheroids. In all other
cases, α ~ 1.0 suggesting an additive effect between PDT and 5-FU.
Radiant Exposure
(J cm-2)
0.3
0.6
1.0

0h

4h

24 h

1.03±0.10
1.18±0.15
1.42±0.22

1.10±0.12
1.15±0.14
1.35±0.19

1.11±0.08
1.01±0.06
1.02±0.06

Table 5 Alpha values for different wash protocols

Spheroid growth kinetics for one trial of each of the three wash protocols are shown in Figure 13
A-C. Not surprisingly, the data show that the PDT + 5-FU protocols result in the greatest growth
inhibition. The PDT effect for spheroids subjected to the 24 h wash protocol was marginal
compared to the 0 and 4 h spheroids.
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A

PDT + 5-FU - 0 h Protocol

Spheroid Volume (% of Control)

1
0.8
5-FU

0.6

0.3 J + 5-FU
0.4

0.72

0.6 J + 5-FU
0.60

0.47

0.2

1.0 J + 5-FU
0.35

0
Treatment

B

PDT + 5-FU - 4 h Protocol

Spheroid Volume (% of Control)

1
0.8
5-FU

0.6

0.3 J + 5-FU
0.4

0.74

0.6 J + 5-FU

0.65

0.54

0.2

0.40

1.0 J + 5-FU

0
Treatment

PDT + 5-FU - 24 h Protocol
Spheroid Volume (% of Control)

1
0.8
5-FU

0.6

0.3 J + 5-FU
0.4

0.73

0.68

0.68

0.2

0.64

0.6 J + 5-FU
1.0 J + 5-FU

0
Treatment
Figure 12 Effects of combined PDT and 5-FU on F98 glioma spheroids subjected to three different wash protocols. Normalized
spheroid volumes were recorded 13 days following light exposure. Each data point represents the mean of 4 trials (12 spheroids
per trial) and error bars represent standard deviations
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A

0 h Protocol
0.4

Control

Volume (mm3)

DC
0.3

0.3 J + 5-FU
0.6 J + 5-FU

0.2

1 J + 5-FU
0.3 J-CONTROL

0.1

0.6 J-CONTROL
0

1 J-CONTROL
0

2

4

6

8

10

12

14

5-FU

Day

B

4 h Protocol
Control

Volume (mm3)

0.5

DC

0.4

0.3 J + 5-FU

0.3

0.6 J + 5-FU

0.2

1 J + 5-FU
0.3 J-CONTROL

0.1

0.6 J-CONTROL

0
0

2

4

6

8

10

12

14

Day

Volume (mm3)

C

1 J-CONTROL
5-FU

24 h Protocol
0.6

Control

0.5

DC

0.4

0.3 J + 5-FU
0.6 J + 5-FU

0.3

1 J + 5-FU

0.2

0.3 J-CONTROL

0.1

0.6 J-CONTROL

0
0

2

4

6

8

10

Day

12

14

16

1 J-CONTROL
5-FU

Figure 13 Growth kinetics of F98 glioma spheroids subjected to three different wash protocols. In each case, treatment was initiated
on day 0. Each data point represents the mean of 12 spheroids. Standard deviations were too small to plot.
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DISCUSSION
PCI is a type of PDT that has been shown to enhance the efficacy of a wide variety of hydrophilic
macromolecules with limited ability to cross the cell membrane (Weyergang et al. 2011). PCI has
been demonstrated in a wide variety of cell lines and in vivo models (Pål Kristian Selbo et al.
2010). Results from the first clinical PCI trial suggest that it may be a useful therapeutic approach
for head and neck cancer patients who have failed standard treatments (Sultan et al. 2016). A
number of in vitro studies employing 3-D multicell glioma spheroids suggest that PCI may be
useful for the delivery of large chemotherapeutic drugs, such as bleomycin, to patients with
malignant brain tumors (Mathews et al. 2012). Bleomycin is a large hydrophilic molecule that
enters the cytosol via endocytosis. In traditional in vitro PCI protocols employing bleomycin, cells
or spheroids are incubated with a membrane-localizing photosensitizer (e.g. AlPcS2a) for 18 h
followed by 4 h incubation with bleomycin. The 4 h incubation, allows a sufficient amount of the
drug to be internalized in endosomes within the cytosol.
Small lipophilic molecules, such as 5-FU, enter the cytosol via passive diffusion across the plasma
membrane and, as such, is not ideally suited for PCI. A recent study showed that PDT enhanced
the efficacy of 5-FU in a synergistic manner in F98 spheroids (Christie et al. 2017). The reason for
the synergism was unknown, but was likely due to an interaction between PDT and 5-FU, rather
than a PCI effect. The thesis experiments, consisting of different wash protocols, were designed to
resolve this issue. A true PCI effect between PDT and 5-FU should be manifested by greater
spheroid growth inhibition following the 4 h wash protocol. If the 0 and 4 h wash protocols produce
similar growth inhibition, a non-PCI interaction between PDT and 5-FU is the likely explanation.
Based on the 5-FU dose response data (Figure 10), the potency of this drug is
approximately five times greater than bleomycin. For example, the 5-FU dose required for a 50%
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reduction in F98 spheroid volume is approximately 0.2 µg/ml. A similar reduction in spheroid
volume was observed following a bleomycin dose of approximately 1 µg/ml (Gonzales et al.
2016).
The PDT dose response data (Figure 11) is in good agreement with previous studies
employing identical spheroids (Christie et al. 2017). For example, Christie et al. observed
normalized spheroid volumes of 85-90% following PDT at a radiant exposure of 0.8 J cm-2. This
compares favorably with the normalized volumes observed for the 0 h PDT protocol (77% at 0.6
J cm-2 and 69% at 1.0 J cm-2). Overall, the data show that PDT efficacy was greatest when
spheroids were irradiated immediately following AlPcS2a incubation (0 h protocol) and least
effective if a 24 h interval was inserted following incubation (24 h protocol). This is not surprising
since one would expect an increasing amount of photosensitizer to diffuse out of the plasma
membrane with time and therefore less AlPcS2a to be available for the PDT effect after 24 h
compared to 0 or 4 h.
The combination of PDT and 5-FU produced an enhanced growth effect compared to that
observed for either modality alone (Figure 12). Although slight differences in normalized spheroid
volumes were observed between 0 and 4 h protocols, none were found to be statistically significant.
This suggests that the observed effect was likely not due to PCI. The similar results obtained for
the two wash protocols suggest that 5-FU enters the cytosol via passive diffusion rather than by
endocytosis which is a requirement for PCI. The calculated alpha values (Table 5) corroborate this
conclusion. Based on the alpha values, a synergistic response was observed only for 0 (α =
1.42±0.22) and 4 (1.35±0.19) h spheroids subjected to the highest light exposure. This is a marginal
synergistic response compared to previous PCI studies with bleomycin where alpha values are
typically in the 2-3 range (Mathews et al. 2012). In all other cases, alpha values were
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approximately unity suggesting a simple additive effect between PDT and 5-FU. Unlike the 0 and
4 h wash protocols, no light dose dependence was observed for the 24 h spheroids, in fact,
normalized volumes for the combined PDT and 5-FU treated spheroids were essentially identical
to the 5-FU only treated spheroids suggesting that the observed effect was almost entirely due to
5-FU. This is consistent with the hypothesis that the photosensitizer had leached out of the plasma
membrane thus negating the PDT effect.
Overall, the data suggest that there is no PCI effect with 5-FU and therefore the weak
synergism observed is likely due to different mechanisms of action of PDT and 5-FU. In contrast
to 5-FU, which inhibits RNA transcription and DNA synthesis (Tiraby et al. 1998), AlPcS2a-PDT
is known to cause damage to the plasma membrane as well as membranes of organelles, such as
lysosomes resulting in hydrolase release and cell death via apoptosis (Guicciardi, Leist, and Gores
2004; Kessel, Vicente, and Reiners 2006; Rodriguez et al. 2009) or autophagy (Inguscio,
Panzarini, and Dini 2012; Reiners et al. 2010).
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CONCLUSIONS
5-FU was found to be a potent cytotoxic agent in the F98 glioma spheroid model and, as such,
only very low concentrations were required for the combined studies investigated in this work.
The PDT dose response was in good agreement with the findings of other studies using identical
spheroids. Not surprisingly, PDT was most efficient following 0 or 4 h wash protocols compared
to 24 h protocols. The combination of PDT and 5-FU was more effective than either treatment
alone, however, no statistically significant differences were observed between the 0 and 4 h wash
protocols suggesting that the observed effects were likely due to different cytotoxic pathways of
PDT and 5-FU. Furthermore, the results are consistent with findings that 5-FU enters the cytosol
via passive diffusion as opposed to endocytosis which is a requirement for PCI.
Future studies could be performed to elucidate the different mechanisms of AlPcS2a-PDT and 5FU in this cell line. AlPcS2a is a membrane localizing photosensitizer found primarily in the plasma
membrane, and to a lesser extent, in membranes of internal organelles such as lysosomes.
Therefore, the type of cell death following light irradiation (PDT) is likely dependent on the wash
protocol. For example, if spheroids are irradiated immediately following the wash (0 h protocol),
necrosis is expected to be the dominant mode of cell death due to damage to the plasma membrane.
Some lysosomal damage is also expected, resulting in apoptotic cell death. In contrast, apoptosis
is expected to be much more prevalent in spheroids subjected to the 4 h wash protocol since the
photosensitizer leaches out of the plasma membrane (while remaining in the lysosome membrane)
during the 4 h interval. One would thus expect a shift from necrotic to apoptotic cell death. The
mode of PDT-induced cell death in response to different wash protocols could be examined by
using commercially available assays for necrosis and apoptosis.
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